185 related articles for article (PubMed ID: 38432118)
41. Description of wylie-stanley agar for the recovery of
Moore JE; Murphy A; Millar BC
Int J Mycobacteriol; 2021; 10(2):166-169. PubMed ID: 34558469
[TBL] [Abstract][Full Text] [Related]
42. In Vitro Efficacy of Free and Nanoparticle Formulations of Gallium(III) meso-Tetraphenylporphyrine against Mycobacterium avium and Mycobacterium abscessus and Gallium Biodistribution in Mice.
Choi SR; Britigan BE; Switzer B; Hoke T; Moran D; Narayanasamy P
Mol Pharm; 2018 Mar; 15(3):1215-1225. PubMed ID: 29421865
[TBL] [Abstract][Full Text] [Related]
43. Rise of Clinical Microbial Proteogenomics: A Multiomics Approach to Nontuberculous Mycobacterium-The Case of Mycobacterium abscessus UC22.
Advani J; Verma R; Chatterjee O; Devasahayam Arokia Balaya R; Najar MA; Ravishankara N; Suresh S; Pachori PK; Gupta UD; Pinto SM; Chauhan DS; Tripathy SP; Gowda H; Prasad TSK
OMICS; 2019 Jan; 23(1):1-16. PubMed ID: 30207826
[TBL] [Abstract][Full Text] [Related]
44. Mycobacterium tuberculosis DprE1 Inhibitor OPC-167832 Is Active against Mycobacterium abscessus
Sarathy JP; Zimmerman MD; Gengenbacher M; Dartois V; Dick T
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0123722. PubMed ID: 36350151
[TBL] [Abstract][Full Text] [Related]
45. Genome-Wide Essentiality Analysis of
Rifat D; Chen L; Kreiswirth BN; Nuermberger EL
mBio; 2021 Jun; 12(3):e0104921. PubMed ID: 34126767
[TBL] [Abstract][Full Text] [Related]
46.
Dong W; Li S; Wen S; Jing W; Shi J; Ma Y; Huo F; Gao F; Pang Y; Lu J
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31791947
[TBL] [Abstract][Full Text] [Related]
47. Drug susceptibility profiles and factors associated with non-tuberculous mycobacteria species circulating among patients diagnosed with pulmonary tuberculosis in Tanzania.
Maya TG; Komba EV; Mensah GI; Mbelele PM; Mpagama SG; Mfinanga SG; Addo KK; Kazwala RR
PLoS One; 2022; 17(3):e0265358. PubMed ID: 35324922
[TBL] [Abstract][Full Text] [Related]
48. Development of a One-Step Multiplex PCR Assay for Differential Detection of Major Mycobacterium Species.
Chae H; Han SJ; Kim SY; Ki CS; Huh HJ; Yong D; Koh WJ; Shin SJ
J Clin Microbiol; 2017 Sep; 55(9):2736-2751. PubMed ID: 28659320
[TBL] [Abstract][Full Text] [Related]
49.
Brown-Elliott BA; Wallace RJ
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288634
[TBL] [Abstract][Full Text] [Related]
50. Gene knock-out in Mycobacterium abscessus using Streptococcus thermophilus CRISPR/Cas.
Akter S; Kamal E; Schwarz C; Lewin A
J Microbiol Methods; 2024 May; 220():106924. PubMed ID: 38548070
[TBL] [Abstract][Full Text] [Related]
51. Isolation and Antimicrobial Susceptibility of Nontuberculous Mycobacteria in a Tertiary Hospital in Korea, 2016 to 2020.
Kim KJ; Oh SH; Jeon D; Chang CL
Tuberc Respir Dis (Seoul); 2023 Jan; 86(1):47-56. PubMed ID: 36480820
[TBL] [Abstract][Full Text] [Related]
52. Performance of Interferon-Gamma Release Assays in the Diagnosis of Nontuberculous Mycobacterial Diseases-A Retrospective Survey From 2011 to 2019.
Yang C; Luo X; Fan L; Sha W; Xiao H; Cui H
Front Cell Infect Microbiol; 2020; 10():571230. PubMed ID: 33680977
[TBL] [Abstract][Full Text] [Related]
53. Prevalence and speciation of non-tuberculous mycobacteria among pulmonary and extrapulmonary tuberculosis suspects in South India.
Thangavelu K; Krishnakumariamma K; Pallam G; Dharm Prakash D; Chandrashekar L; Kalaiarasan E; Das S; Muthuraj M; Joseph NM
J Infect Public Health; 2021 Mar; 14(3):320-323. PubMed ID: 33618276
[TBL] [Abstract][Full Text] [Related]
54. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease.
Lyu J; Kim BJ; Kim BJ; Song JW; Choi CM; Oh YM; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2014 Nov; 108(11):1706-12. PubMed ID: 25245792
[TBL] [Abstract][Full Text] [Related]
55. Mycobacterium abscessus lung disease in a patient with previous pulmonary tuberculosis.
Hongfei D; Xuerui H; Jing W; Naihui C
Southeast Asian J Trop Med Public Health; 2012 Jul; 43(4):959-63. PubMed ID: 23077819
[TBL] [Abstract][Full Text] [Related]
56. Nontuberculosis mycobacterial infections at a specialized tuberculosis treatment centre in the Republic of Korea.
Yoon HJ; Choi HY; Ki M
BMC Infect Dis; 2017 Jun; 17(1):432. PubMed ID: 28619015
[TBL] [Abstract][Full Text] [Related]
57. Epidemiology of Nontuberculous Mycobacteria in Nanjing and
Zhang R; Luo S; Wang N; Zhang H; Wu X
Infect Drug Resist; 2023; 16():2751-2764. PubMed ID: 37180636
[TBL] [Abstract][Full Text] [Related]
58. Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in
Raynaud C; Daher W; Johansen MD; Roquet-Banères F; Blaise M; Onajole OK; Kozikowski AP; Herrmann JL; Dziadek J; Gobis K; Kremer L
ACS Infect Dis; 2020 Feb; 6(2):324-337. PubMed ID: 31860799
[TBL] [Abstract][Full Text] [Related]
59. Nontuberculous mycobacteria isolated during the treatment of pulmonary tuberculosis.
Jun HJ; Jeon K; Um SW; Kwon OJ; Lee NY; Koh WJ
Respir Med; 2009 Dec; 103(12):1936-40. PubMed ID: 19576745
[TBL] [Abstract][Full Text] [Related]
60. Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins.
Ganapathy US; Lan T; Dartois V; Aldrich CC; Dick T
Microbiol Spectr; 2023 Sep; 11(5):e0190023. PubMed ID: 37681986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
